CNS Market Access in China - Investment in mental health services offers growth opportunities for psychiatry players

Introduction

China’s expanding and aging population makes the country an attractive market for manufacturers of CNS products. Key CNS drug launches to have taken place in China in recent years include: Keppra (levetiracetam) for epilepsy in 2007, Champix (varenicline) for smoking cessation in 2008 and Invega (paliperidone) for schizophrenia in 2009.

Features and benefits

• Quantify the prevalent cases of key CNS conditions in China in 2010.
• Review the current treatment of key CNS conditions in China and published treatment guidelines.
• Identify the major multinational and domestic players in the Chinese CNS market. Understand the composititon of their CNS portfolios.
• Examine the major strengths and weaknesses of the current Chinese CNS market. Understand the key opportunites and threats facing developers.
• This report is authored by an analyst and epidemiologist based in China.

Highlights

Delivery of psychiatry services in China is hindered by a shortage of qualified psychiatrists. This situation poses a key barrier to the diagnosis and treatment of psychiatric conditions in China. Follow-up services for patients suffering from mental health conditions are also weak.
The Chinese government is prioritizing mental health care and has taken steps to improve the treatment of mental health conditions in the country. The next 10 years are likely to witness a substantial increase in access to mental health services in China, thereby representing a key opportunity to players in the psychiatry sector of the CNS market.
A key threat to the uptake of CNS drugs in China is the stigma that continues to surround several CNS conditions including not only mental illnesses but neurological conditions such as Alzheimer’s disease and epilepsy. Such stigma deters patient presentation, which in turn, hinders diagnosis and treatment.

Your key questions answered

• How many prevalent cases of key CNS condititons are there in China?
• Which are the most active multinational and domestic pharmaceutical companies in the Chinese CNS market?
• How are neurology, psychiatry and pain services organized and delivered in China? What are the typical patient care pathways for key CNS conditions?
• What are the key opportunities for existing and prospective players? What are the major threats to the uptake of CNS drugs in China?
• What strategies can companies implement in order to achieve maximum penetration in the Chinese CNS market?

Table Of Contents

Executive Summary
Strategic scoping and focus
Datamonitor insight into the central nervous system market in China
Related reports

OVERVIEW
Catalyst
Summary

EPIDEMIOLOGY OF KEY CNS CONDITIONS IN CHINA
Key findings
Alzheimer’s disease
Overview
Sources
Methods and Results
Epilepsy
Overview
Sources
Methods and Results
Depression
Overview
Sources
Methods and Results
Schizophrenia
Overview
Sources
Methods and Results
Cancer pain
Overview
Sources
Methods and Results

MARKET OVERVIEW
Key findings
Introduction
Organization and delivery of CNS services in China
Neurological services
Psychiatry services
Pain services in China
Treatment of key CNS conditions in China
Treatment guidelines for Alzheimer’s disease
Treatment guidelines for epilepsy
Treatment guidelines for schizophrenia
Treatment guidelines for depression
Treatment guidelines for cancer pain
Patient care pathways for key CNS conditions in China
Alzheimer’s disease
Epilepsy
Schizophrenia
Depression
Cancer pain

KEY COMPANIES IN THE CHINESE CNS MARKET
Key findings
Multinational corporations
AstraZeneca
Johnson & Johnson
Eli Lilly
Pfizer
GlaxoSmithKline
Lundbeck
Domestic players
Shandong Qilu Pharma
Simcere
Hubei Yiyao Pharma
Recent deals and alliances in the CNS sector in China
Lundbeck sought to increase penetration of the Chinese CNS market through three deals over 2008–10

MARKET ACCESS
Key findings
SWOT analysis of the Chinese CNS market
Strengths
Weaknesses
Opportunities
Threats
Strategies for market penetration
Big Pharma would benefit from establishing a balanced CNS portfolio in China
Multinational companies must manage their turnover rate in China
Joint venture and local alliance remain the most popular ways to establish local presence in China
Awareness of regional disparities is crucial for commercial success
Develop and implement educational campaigns to reduce stigma surrounding CNS conditions

BIBLIOGRAPHY
Books and journal papers
Websites
Datamonitor reports

APPENDIX
Contributing experts
Conferences attended
Report methodology